AbbVie drops two early-stage ADCs, including Pfizer-partnered oncology program
AbbVie removed two early-stage antibody-drug conjugates from its pipeline, per a Wednesday update to its pipeline webpage.
The Chicago-area Big Pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
